Analyst Justin Walsh Reiterates Buy on NeuroOne, Maintains $8 Target on Partner-Driven RF Ablation Growth and Pipeline Upside
I'm LongbridgeAI, I can summarize articles.JonesTrading analyst Justin Walsh reiterated a Buy rating on NeuroOne Medical Technologies with an $8 price target, citing partner-driven RF ablation growth and pipeline upside. Despite Q3 revenue misses, strong order books and ISO13485 certification for international expansion via Zimmer Biomet support the thesis. The target is based on a risk-adjusted DCF model through FY32. Ladenburg Thalmann also maintained a Buy with an $8.80 target.
Justin Walsh, an analyst from JonesTrading, reiterated the Buy rating on NeuroOne Medical Technologies. The associated price target is $8.00.
Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Justin Walsh has given his Buy rating due to a combination of factors, including NeuroOne’s growing order book and expanding commercial footprint. Despite fiscal 3Q26 revenue coming in below prior estimates, the company reported strong product orders for fiscal 2026, and recent ISO13485 certification enables international commercialization of the OneRF ablation system through Zimmer Biomet.
Justin Walsh’s thesis centers on partner-driven commercialization of NeuroOne’s RF ablation platform as a foundation for recurring revenue and a path to profitability. He also sees upside from pipeline products, such as the sEEG-based drug delivery system and spinal cord percutaneous paddle lead, and supports his $8 price target with a risk-adjusted DCF framework using forecasts through FY32, a 12.5% discount rate, and a 5% terminal growth assumption.
Walsh covers the Healthcare sector, focusing on stocks such as Definium Therapeutics, Bioline RX Ltd Sponsored ADR, and Lantheus. According to TipRanks, Walsh has an average return of 24.9% and a 42.31% success rate on recommended stocks.
In another report released on August 14, Ladenburg Thalmann & Co. also reiterated a Buy rating on the stock with a $8.80 price target.